Small Molecule · MT1988

MT1988 (tropisetron/varenicline)

Oral, twice-daily fixed-dose combination of two well-established nicotinic-acting small molecules - tropisetron (a 5-HT3 antagonist that is also a potent, selective alpha7 nicotinic receptor partial agonist) and varenicline (an alpha4beta2 nicotinic receptor partial agonist) - in development by Monument Therapeutics (Manchester, UK) for cognitive impairment associated with schizophrenia (CIAS), as an add-on to existing antipsychotics. The pairing is designed to mitigate a prevalent off-target side effect of nicotinic agonists. A Phase 1 multiple-dose study in 42 healthy adults (14 days, four dose levels vs placebo) completed in April 2025; the drug was generally well tolerated with no severe or serious adverse events. A Phase 1/2 proof-of-principle study in ~150 young people at clinical high risk for psychosis, run with the FNIH-managed Accelerating Medicines Partnership Schizophrenia (AMP SCZ) programme, dosed its first patient in March 2026.

Also known as: MT1988, MT-1988, MT 1988, tropisetron/varenicline

Key facts

Modality
Small molecule
Mechanism
alpha7 nAChR Partial agonist
Highest phase
Phase 1/2
Lead indication
Schizophrenia
Trials
2 tracked · 1 recruiting
Next catalyst
September 2027 — Registry results (Schizophrenia)

Mechanism of action#

Dual-component nicotinic strategy. Tropisetron, marketed outside the US as a 5-HT3 receptor antagonist antiemetic, is a potent and selective partial agonist at alpha7 nicotinic acetylcholine receptors, a long-pursued pro-cognitive target in schizophrenia. Varenicline, the approved smoking-cessation drug, is an alpha4beta2 nicotinic receptor partial agonist. Monument's patent frames the combination as addressing positive, negative and cognitive symptoms while mitigating the gastrointestinal side effects that alpha7 agonists have shown in trials, attributed to 5-HT3 activity; Monument describes the combination as designed to remediate a prevalent off-target side effect of nicotinic agonists.

TargetActionAffinity
alpha7 nAChRprimaryCHRNA7Partial agonist—ⓘ
5-HT3 receptorHTR3AAntagonist—ⓘ
alpha4beta2 nAChRCHRNA4Partial agonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
MT1988 oral fixed-dose combination (twice daily)
Oral, twice daily. Phase 1 (NCT06728176): four dose levels vs placebo for 14 days in healthy adults. Phase 1/2 (NCT07226895): low dose and high dose vs placebo, twice daily for 8 weeks. Absolute doses of each component are not disclosed.
OralTwice daily—

Development timeline#

Jan 25Jul 25Jan 26Jul 26Jan 27Jul 27TodayPhase 1/230 Sept 2027 — upcoming — ClinicalTrials.gov estimated primary completion of the Phase 1/2 MT1988 proof-of-principle study in clinical high risk for psychosis (NCT07226895): September 2027.30 Apr 2026 — Patent granted — US patent 12,594,270 granted for MT198810 Mar 2026 — Trial started — First patient dosed in MT1988 Phase 1/2 study in clinical high risk for psychosis3 Mar 2026 — phase change — Phase 1/2 proof-of-principle study NCT07226895 in participants at clinical high risk for psychosis started (registry actual start 2026-03-03); Monument announced first patient dosed on 2026-03-10.15 Oct 2024 — Financing — Monument Therapeutics secures GBP 1M equity investment from the Forster FoundationPhase 119 Aug 2025 — Partnership — Monument partners with FNIH to evaluate MT1988 within AMP Schizophrenia23 Jun 2025 — readout (met) — Phase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II.8 Apr 2025 — phase change — Phase 1 primary completion (actual) per registry; Monument announced positive Phase I results on 2025-06-23 (generally well tolerated, no severe or serious AEs).25 Feb 2025 — Financing — Monument Therapeutics secures GBP 850k to advance MT198825 Nov 2024 — phase change — First clinical study of MT1988 started: Phase 1 multiple-dose safety/PK study in healthy adults (NCT06728176, SCZ103) at BDD Pharma; announced 2024-11-26.25 Nov 2024 — Trial started — First clinical study of MT1988 starts (Phase 1, healthy adults)
Phase change Readout Event UpcomingHover a marker for details.
Phase 1/2Oct 2024 – Sept 2027
  1. UpcomingClinicalTrials.gov estimated primary completion of the Phase 1/2 MT1988 proof-of-principle study in clinical high risk for psychosis (NCT07226895): September 2027.
  2. Patent grantedUS patent 12,594,270 granted for MT1988↗
  3. Trial startedFirst patient dosed in MT1988 Phase 1/2 study in clinical high risk for psychosis↗
  4. Phase 1/2 proof-of-principle study NCT07226895 in participants at clinical high risk for psychosis started (registry actual start 2026-03-03); Monument announced first patient dosed on 2026-03-10.
  5. FinancingMonument Therapeutics secures GBP 1M equity investment from the Forster Foundation↗
Phase 1Nov 2024 – Aug 2025
  1. PartnershipMonument partners with FNIH to evaluate MT1988 within AMP Schizophrenia↗
  2. metPhase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II.↗
  3. Phase 1 primary completion (actual) per registry; Monument announced positive Phase I results on 2025-06-23 (generally well tolerated, no severe or serious AEs).
  4. FinancingMonument Therapeutics secures GBP 850k to advance MT1988↗
  5. First clinical study of MT1988 started: Phase 1 multiple-dose safety/PK study in healthy adults (NCT06728176, SCZ103) at BDD Pharma; announced 2024-11-26.
  6. Trial startedFirst clinical study of MT1988 starts (Phase 1, healthy adults)↗

MT1988 (tropisetron/varenicline) for Schizophrenia#

Phase 1/2RecruitingSchizophrenia indication →

MT1988, Monument Therapeutics' fixed-dose combination of tropisetron (alpha7 nicotinic partial agonist / 5-HT3 antagonist) and varenicline (alpha4beta2 nicotinic partial agonist), for cognitive impairment associated with schizophrenia (CIAS), intended as add-on to antipsychotics. A Phase 1 multiple-dose safety/PK study in healthy adults (NCT06728176, 42 enrolled, 14-day dosing at four dose levels vs placebo) ran November 2024 to April 2025; Monument reported it was generally well tolerated with no severe or serious adverse events and that results support advancement into Phase 2. The program's first patient study is not in diagnosed schizophrenia but in people at clinical high risk (CHR) for psychosis: NCT07226895 (SCZ201), a Phase 1/2, 8-week, randomised, double-blind, placebo-controlled proof-of-principle study of two MT1988 doses in ~150 participants aged 17-30, run within the FNIH-managed AMP SCZ programme with NIMH as collaborator. Primary endpoints are change at week 8 in verbal memory (PennCNB list learning), attenuated positive symptoms (PSYCHS) and negative symptoms (NSI-PR). First patient dosed March 2026; estimated primary completion September 2027. No efficacy data have been reported.

Readouts

  • September 2027AnticipatedRegistry resultsNCT07226895

    ClinicalTrials.gov estimated primary completion of the Phase 1/2 MT1988 proof-of-principle study in clinical high risk for psychosis (NCT07226895): September 2027.

  • 2025-06-23ReportedTopline datametNCT06728176

    Phase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II. ↗

Clinical trials#

NCT07226895SCZ201Phase 1/2Recruitingn=150

A Study to Explore Changes in Cognitive, Clinical, Biological and Digital Measures Following 8 Weeks of Twice-daily Dosing of MT1988 and to Evaluate Safety & Tolerability of MT1988, in Participants at Clinical High Risk (CHR) for Psychosis

Started Mar 2026· Primary completion Sept 2027

NCT06728176SCZ103Phase 1Completedn=42

A Single Centre, Double Blinded, Randomised, Parallel Arm, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of MT1988 in Healthy Adults

Started Nov 2024· Primary completion Apr 2025

Conference coverage#

MT1988 appears in 1 CNS Pulse conference abstract:

Sources#

  1. Coe JW, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-7 — PubMed
  2. Macor JE, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001;11(3):319-21 — PubMed
  3. Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis (2026-03-10) — Monument Therapeutics
  4. Monument Therapeutics Announces Grant of US Patent for MT1988 (2026-04-30) — Monument Therapeutics
  5. Monument Therapeutics Announces Partnership with FNIH for Clinical Trial of MT1988 (2025-08-19) — Monument Therapeutics
  6. Monument Therapeutics Launches First Clinical Study of MT1988 (2024-11-26) — Monument Therapeutics
  7. Monument Therapeutics Reports Positive Phase I Results for Novel CIAS Treatment (2025-06-23) — Monument Therapeutics
  8. Monument Therapeutics Secures GBP 1M Investment to Fund its Schizophrenia Programme (2024-10-15) — Monument Therapeutics
  9. Monument Therapeutics Secures GBP 850k to Advance Schizophrenia Treatment (2025-02-25) — Monument Therapeutics
  10. NCT06728176 (SCZ103) - Safety and PK of Multiple Doses of MT1988 in Healthy Adults — ClinicalTrials.gov (U.S. National Library of Medicine)
Show all 11 sources
  1. NCT07226895 (SCZ201) - MT1988 in Participants at Clinical High Risk for Psychosis — ClinicalTrials.gov (U.S. National Library of Medicine)